PacBio (NASDAQ: PACB), announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics.

Spear Bio Inc., announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Revvity, Inc. announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc.

Revvity, Inc. (NYSE: RVTY), announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone.

Bio-Rad leads investment to support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.

AMSBIO has implemented a program of investment to support the students at Penn State Lehigh Valley, part of Pennsylvania State University, in their transformative Course-based Undergraduate Research Experience (CURE) program.

Thermo Fisher Scientific has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for the Applied BioSystems™ TaqPath™ COVID-19 Diagnostic PCR Kit.

Revvity, Inc. (NYSE: RVTY), announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom.

Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced updates on its oncology assay portfolio and regulatory milestones, ahead of its presence at the AMP 2024 meeting.